Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA.
Company Details
- Employees
- 27
- Address
- Waltham, Ma, Us
- Industry
- Biotechnology
- Website
- http://www.avilar-tx.com/
- HQ
- Waltham, MA
Avilar Therapeutics Questions
Avilar Therapeutics's website is http://www.avilar-tx.com/
Avilar Therapeutics's LinkedIn profile is https://www.linkedin.com/company/avilar-therapeutics
Avilar Therapeutics has
27 employees.
View email and phone details for 27
employees at Avilar Therapeutics.
Avilar Therapeutics's industry is
Biotechnology
Avilar Therapeutics's top competitors are
Aera Therapeutics,
Chroma Medicine,
Raven (Ra Ventures),
Odyssey Therapeutics,
Nested Therapeutics,
Seaport Therapeutics,
Beam Therapeutics,
Triana Biomedicines,
Kymera Therapeutics,
Nvelop Therapeutics.
Avilar Therapeutics's categories are Biotechnology
